Retreatment with interferon plus ribavirin in chronic hepatitis C patients with genotype 1 who had no response or a relapse with a previous interferon treatment. Long-term follow-up;Retratamiento con interferón más ribavirina en pacientes con hepatitis crónica C, genotipo 1, no respondedores o con recaída tras un tratamiento previo con interferón. Seguimiento a largo plazo

Revista Espanola de Quimioterapia

Volumn 15, Issue 3, 2002, Pages 247-256

  Olasol, Vicente ^a   Cordoba J ^a   Molina, J M ^a   Lopez B ^a   Siles, M S ^a   Jaen J ^a   Martinez F ^a   Calvo, F ^a   Garijo, R ^a   Gobernado, M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Chronic hepatitis C; Interferon plus ribavirin

Indexed keywords

INTERFERON; REBETRON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; RELAPSE; RETREATMENT; TREATMENT FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; GENETICS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TIME;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; PROSPECTIVE STUDIES; RECURRENCE; RIBAVIRIN; TIME FACTORS;

EID: 1842865888     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Anonymous. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997; 26: 2S-10S.
2. Hoofnagle, J.H., Di Bisceglie, A.M. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
3. Dhumeaux, D., Doffoel, M., Galmiche, J.P. A French consensus conference on hepatitis C: Screening and treatment. J Hepatol 1997; 27: 941-944.
4. Powell, D.W., Abramson, B.Z., Balint, J.A. y cols. National Institutes of Health Consensus Development Conference. Panel statement: Management of hepatitis C. Hepatology 1997; 26 (Suppl. 1): 2S-10S.
5. Ning, Q., Brown, D., Parodo, J. y cols. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves Th1 cytokine production, but inhibits Th2 cytokine response. J Immunol 1998; 160: 3487-3493.
6. Hultgren, C., Milich, D.R., Weiland, O., Sallberg, M. The antiviral compound ribavirin modulates T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79: 2381-2392.
7. McHutchison, J., Gordon, S., Schiff, E. y cols. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
8. Poynard, T., Marcellin, P., Lee, S. y cols. Randomised trial of interferon 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
9. Lai, M.Y., Kao, J.H., Yang, P.M. y cols. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-1312.
10. Reichard, O., Norkrans, G., Fryden, A., Braconier, J.H., Sonnenborg, A., Weilland, O. Randomised, double-blind, placebo-controlled trial of interferon alpha 2b with an without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.
11. Barbaro, G., Di Lorenzo, G., Soldini, M. y cols. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: An Italian multicenter experience. Ribavirin-interferon in chronic hepatitis Italian group investigators. J Hepatol 2000; 3: 448-455.
12. Schalm, S.W., Hansen, B.E., Chemello, L. y cols. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26: 961-966.
13. Davis, G.L., Esteban-Mur, R., Rustgi, V. y cols. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-1499.
14. Bellobuono, A., Mondazzi, L., Tempini, S., Silini, E., Vicari, F., Ideo, G. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: A randomized clinical trial. J Viral Hepat 1997; 4: 185-191.
15. Enríquez, J., Gallego, A., Torras, X. y cols. Retreatment for 24 vs 48 weeks with interferon-2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat 2000; 7: 403-408.
16. Marco, V.D., Almasio, P., Vaccaro, A. y cols. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. J Hepatol 2000; 33: 456-462.
17. Lo Iacono, O., Castro, A., Diago, M. y cols. Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. Aliment Pharmacol Ther 2000; 14: 463-469.
18. Ferenci, P., Stauber, R., Steindl-Munda, P. y cols. Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C. J Viral Hepat 1999; 6 (Suppl. 1): 53-58.
19. Barbaro, G., Di Lorenzo, G., Belloni, G. y cols. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial. Am J Med 1999; 107: 112-118.
20. Kronenberger, B., Rüster B., Elez R. y cols. Interferon alfa downregulates CD81 in patients with chronic hepatitis C. Hepatology 2001; 33: 1518-1526.
21. Stuyver, L., Rossau, R., Wyscur, A. y cols. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1003; 74: 1093-1102.
22. Simmonds, P., Alberti, P., Alter, J. y cols. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
23. Detmer, J., Lagier, R., Flynn, J. y cols. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 1996; 34: 901-907.
24. Knodell, R.G., Ishak, K.G., Black, W.C. y cols. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
25. Schvarcz, R., Glaumann, H., Reichard, O., Weiland, O. Histological and virological long-term outcome in patients treated with interferon-alpha 2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999; 6: 237-242.
26. Lai, M.Y., Kao, J.H., Yang, P.M., Wang, J.T., Chen, P.J., Chu, J.S. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-1312.
27. Fontaine, H., Chaix, M.L., Lagneau, J.L., Brechot, C., Pol, S. Recovery from hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet 2000; 356: 41.
28. Olaso, V., Córdoba, J., Berenguer, M. y cols. Tratamiento con interferón-α en la hepatitis crónica C: Implicaciones clínicas, histológicas y virológicas. Rev Esp Enf Digest 1997; 89: 531-540.
29. Lindsay, K.L. Therapy of chronic hepatitis C: Overview. Hepatology 1997; (Suppl. 1): 71S-77S.
30. Davis, G.L. New schedules of interferon for chronic hepatitis C. J Hepatol 1999; 31 (Suppl. 1): 227-231.
31. Shiffman, M.L., Hofmann, C.M., Gabbay, J. y cols. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: Effects of higher doses of interferon and ribavirin combination therapy. The Virginia cooperative hepatitis treatment group. Am J Gastroenterol 2000; 95: 2928-2935.
32. Pol, S., Nalpas, B., Bourliere, M. y cols. Combination of ribavirin and interferon-alfa surpases high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. Hepatology 2000; 31: 1338-1344.
33. Bekkering, F.C., Stalgis, C., Hutchison, J.G., Brouwer, J.T, Perelson, A.S. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 33: 419-423.
34. Brillanti, S., Levantesi, F., Masi, L., Foli, M., Bolondi, L. Triple antiviral as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32: 630-634.
35. Poynard, T., McHutchinson, J., Davis, G.L. y cols. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-1137.
36. Pol, S., Couzigou, P., Bourliere, M. y cols. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter study group under the coordination of the Necker Hospital, París, France. J Hepatol 1999; 31: 1-7.
37. Schvarcz, R., Glaumann, H., Reichard, O., Weiland, O. Histological and virological long-term outcome in patients treated with interferon-alpha 2b and ribavirin for chronic hepatitis C. J Viral Hepat 1999; 6: 237-242.
38. Reichard, O., Glaumann, H., Fryden, A., Norkrans, G., Wejstal, R., Weiland, O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-inteferon. J Hepatol 1999; 30: 783-787.
39. Camma, C., Di Marco, V., Lo Iacono, O. y cols. Log-term course of interferon-treated chronic hepatitis C. J Hepatol 1998; 28: 531-537.
40. Marcellin, P., Boyer, N., Gervais, A. y cols. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-881.
41. Romeo, R., Pol, S., Berthelot, P., Brechot, C. Eradication of hepatitis C virus RNA after-interferon therapy. Ann Intem Med 1994; 121: 276-277.